Does Previous Anti-thrombotic Use Affect the Course of Coronavirus Disease-2019?

Introduction: Proinflammatory cytokines, produced as an immune response in severe acute respiratory syndrome- coronavirus 2 infection, activate the coagulation cascade as well. In this study, we investigated the difference in the clinical course of patients who had been already using anti-thrombotic...

Full description

Saved in:
Bibliographic Details
Published inIstanbul medical journal Vol. 23; no. 4; pp. 301 - 305
Main Authors Onur, Imran, Onur, Seda Tural, Gunluoglu, Gulsah, Bingol, Gulsum, Sokucu, Sinem Nedime, Ozden, Ozge, Nasifov, Muharrem, Bolat, Erkut, Toptas, Mehmet, Altin, Sedat
Format Journal Article
LanguageEnglish
Turkish
Published Istanbul Galenos Yayinevi Tic. Ltd 01.11.2022
Galenos Publishing House
Galenos Yayinevi
Subjects
anti-trombotic treatments
Aspirin
Care and treatment
Clopidogrel
Comorbidity
Comparative analysis
Coronaviruses
COVID-19
Cytokines
Disease
Enzymes
Health aspects
Hospitalization
Hospitals
Immune response
Intubation
Kinases
Laboratories
Length of stay
Medical research
Medicine, Experimental
Mortality
Observational studies
Pandemics
Pathophysiology
Patients
Pulmonary arteries
Regression analysis
sars-cov-2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Thoracic surgery
Thrombosis
Ventilators
Online AccessGet full text

Cover

More Information
Summary:Introduction: Proinflammatory cytokines, produced as an immune response in severe acute respiratory syndrome- coronavirus 2 infection, activate the coagulation cascade as well. In this study, we investigated the difference in the clinical course of patients who had been already using anti-thrombotic therapy before coronavirus disease-2019 (COVID-19) for any reason compared to the group who had not. Methods: In this retrospective, multicenter study; patients who were hospitalized between March 11 and July 1, 2020 were divided into two main groups as who had been on anti-thrombotic therapy for any indication use previously at the time of admission or who had not been on anti-thrombotic therapy at the time of admission, and their selected clinical parameters were compared. Results: After analyzing the study population of 124 patients with a homogeneous distribution in terms of age and gender, the comparison of anti-thrombotic users and non-users showed no significant difference in hospitalization. There was a statistically significant decrease in mechanical ventilation apply rate, intensive care unit duration and mortality rate between the group using anti-thrombotic compared to the group not using it (p<0.05). Conclusion: It has already been shown that COVID-19 patients are more prone to thromboembolic events as it activates the coagulation cascade with the cytokine storm it creates and thus the mortality of COVID-19 infection increases significantly. Parallel to this fact the results of our study demonstrated that using anti-thrombotic therapy for any reason may affect the bad prognosis of the disease positively. Keywords: SARS-CoV-2, COVID-19, anti-trombotic treatments
ISSN:2619-9793
1304-8503
2148-094X
DOI:10.4274/imj.galenos.2022.49035